![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers
|
|
|
Reported by Jules Levin
IAS 2013 Kuala Lumpur, Malaysia June 30-July 3
Thomas N Kakuda,1 Tom Van De Casteele,2 Romana Petrovic,2 Magda Opsomer,2 Frank Tomaka,1 Joseph Mrus,3 Richard MW Hoetelmans2
1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen Infectious Diseases BVBA, Beerse, Belgium; 3Janssen Global Services, Titusville, NJ, USA
![IAS1.gif](../images/071813/071813-3/IAS1.gif)
![IAS2.gif](../images/071813/071813-3/IAS2.gif)
![IAS3.gif](../images/071813/071813-3/IAS3.gif)
![IAS4.gif](../images/071813/071813-3/IAS4.gif)
![IAS5.gif](../images/071813/071813-3/IAS5.gif)
![IAS6.gif](../images/071813/071813-3/IAS6.gif)
![IAS7.gif](../images/071813/071813-3/IAS7.gif)
![IAS8.gif](../images/071813/071813-3/IAS8.gif)
![IAS9.gif](../images/071813/071813-3/IAS9.gif)
![IAS10.gif](../images/071813/071813-3/IAS10.gif)
![IAS11.gif](../images/071813/071813-3/IAS11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|